Harding Loevner LP Vertex Pharmaceuticals Inc Transaction History

Harding Loevner LP

$14.4 Billion
Q4 2024

A detailed history of Harding Loevner LP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Harding Loevner LP holds 823,627 shares of VRTX stock, worth $414 Million. This represents 2.31% of its overall portfolio holdings.

Number of Shares

823,627

Previous 1,152,625 28.54%

Holding current value

$414 Million

Previous $536 Million 38.13%

% of portfolio

2.31%

Previous 3.14%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$396.64 - $516.74 $130 Million - $170 Million	-328,998 Reduced 28.54%	823,627 $332 Million
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $14.6 Million - $16.1 Million	-31,783 Reduced 2.68%	1,152,625 $536 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $15.2 Million - $18.8 Million	-38,630 Reduced 3.16%	1,184,408 $555 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $40 Million - $43.8 Million	-98,191 Reduced 7.43%	1,223,038 $511 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $8.75 Million - $10.5 Million	-25,522 Reduced 1.9%	1,321,229 $538 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $64.8 Million - $69.4 Million	-191,519 Reduced 12.45%	1,346,751 $468 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $90.7 Million - $101 Million	-288,354 Reduced 15.79%	1,538,270 $541 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $3.94 Million - $4.49 Million	-13,897 Reduced 0.76%	1,826,624 $576 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $57.4 Million - $64.5 Million	200,704 Added 12.24%	1,840,521 $532 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $25.7 Million - $28.7 Million	-93,874 Reduced 5.41%	1,639,817 $475 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $8.36 Million - $10.4 Million	-35,585 Reduced 2.01%	1,733,691 $489 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $24.9 Million - $29.4 Million	-112,595 Reduced 5.98%	1,769,276 $417 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $5.17 Million - $6.53 Million	-29,232 Reduced 1.53%	1,881,871 $413 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $16 Million - $17.9 Million	-87,975 Reduced 4.4%	1,911,103 $347 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $3 Million - $3.54 Million	15,989 Added 0.81%	1,999,078 $403 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $12.4 Million - $14.5 Million	-60,006 Reduced 2.94%	1,983,089 $426 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $8.81 Million - $11.7 Million	42,554 Added 2.13%	2,043,095 $483 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $5.43 Million - $6.43 Million	-21,226 Reduced 1.05%	2,000,541 $544 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $5.75 Million - $7.54 Million	-25,507 Reduced 1.25%	2,021,767 $587 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $8.87 Million - $11 Million	-44,382 Reduced 2.12%	2,047,274 $487 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $38.6 Million - $51.8 Million	-231,426 Reduced 9.96%	2,091,656 $458 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $263 Million - $296 Million	1,582,711 Added 213.77%	2,323,082 $394 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $1.92 Million - $2.22 Million	-11,673 Reduced 1.55%	740,371 $136 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $123 Million - $146 Million	751,975 Added 1089818.88%	752,044 $138 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $10,481 - $13,262	69 New	69 $11,000

Others Institutions Holding VRTX

# of Institutions

1,764

Shares Held

228M

Call Options Held

1.63M

Put Options Held

1.47M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harding Loevner LP, based on Form 13F filings with the SEC.

News

Stay updated on Harding Loevner LP with notifications on news.

Account

Harding Loevner LP Vertex Pharmaceuticals Inc Transaction History